文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19相关ARDS中ACE2表达增加及肺泡II型细胞丢失

Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19-related Acute Respiratory Distress Syndrome.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01
一句话结论COVID-19相关与非相关ARDS均见肺组织及血清ACE2上调、ACE下降,但AT2细胞减少仅见于COVID-19相关ARDS。

该回顾性队列研究采用多重免疫荧光染色和血清检测,比较COVID-19相关ARDS、非相关ARDS及对照者的肺组织ACE2/ACE表达与AT2/内皮细胞分布。结果:两类ARDS肺组织ACE2均升高(0.06%和0.12% vs 对照0.006%),内皮细胞ACE2上调而AT2细胞ACE2未上调;两类ARDS肺ACE均降低,血清ACE2升高、ACE降低模式相似。COVID-19相关ARDS的AT2细胞较非相关ARDS显著减少(1.395% vs 2.94%,P=0.0033)。提示AT2丢失是COVID-19相关ARDS的选择性特征。

要点

  • COVID-19相关与非相关ARDS肺组织ACE2均升高:分别为组织面积0.06%和0.12%,对照0.006%(P=0.013和P<0.0001)。
  • ACE2上调见于内皮细胞(0.32%和0.53% vs 0.01%;P=0.009和P<0.0001),AT2细胞ACE2未见上调(P=0.94和P=0.44)。
  • 两类ARDS肺组织ACE表达均降低(P=0.057和P=0.032),血清ACE2升高、ACE降低模式相似。
  • AT2细胞减少仅见于COVID-19相关ARDS:1.395% vs 非相关ARDS 2.94%(P=0.0033)。
  • 该研究为回顾性双队列设计,不能据此推导ACE2/ACE作为床旁生物标志物或治疗靶点的阈值。

适用人群与场景

  • 研究纳入COVID-19相关ARDS、COVID-19非相关ARDS患者及对照者,来源于两个不同队列的回顾性肺组织与血清样本。
  • 原文未提及具体纳入/排除标准、ICU/急诊场景及病情阶段。

诊断标准与关键阈值

  • ARDS诊断依据原文未提及具体标准名称或界值。
  • ACE2/ACE表达以多重免疫荧光染色组织面积百分比及血清浓度表示,原文未给出临床决策阈值。

处置流程与药物剂量

  • 原文未提及针对ACE2/ACE或AT2细胞的治疗干预、药物剂量或处置流程。

红旗征与不能漏的情况

  • 原文未提及需要立刻处理或不能漏诊的红旗征及对应处理。

研究设计与关键结果

  • 回顾性双队列研究:COVID-19相关与非相关ARDS肺组织ACE2均高于对照(0.06%和0.12% vs 0.006%;P=0.013和P<0.0001)。
  • ACE2在内皮细胞上调(0.32%和0.53% vs 0.01%;P=0.009和P<0.0001),AT2细胞无上调(0.13%和0.08% vs 0.03%;P=0.94和P=0.44)。
  • 两类ARDS肺组织ACE降低(P=0.057和P=0.032);血清ACE2升高(COVID-19 P=0.0054,非COVID-19 P<0.0001)、ACE降低(P<0.0001和P=0.016)。
  • COVID-19相关ARDS的AT2细胞低于非相关ARDS(1.395% vs 2.94%,P=0.0033)。

证据类型、等级与局限

  • 证据类型:回顾性双队列研究(肺组织多重免疫荧光染色与血清检测),非RCT。
  • 局限:回顾性设计、样本量未在摘要中报告、未提及盲法与混杂控制;不能从相关性推导因果或临床阈值。

对床旁实践的改变

  • 该研究不支持将ACE2/ACE或AT2细胞计数作为急诊/ICU床旁常规检测或决策指标,原文未给出阈值。
  • AT2细胞选择性丢失仅见于COVID-19相关ARDS,提示两类ARDS可能存在不同的肺泡上皮修复机制,但原文未提出对应治疗改变。
  • 不改变现有ARDS支持治疗流程;原文未涉及任何药物剂量或干预方案。

指南或共识出处

  • 原文未提及指南或共识出处;来源为Am J Respir Crit Care Med研究论文。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

Rationale: ACE2 (angiotensin-converting enzyme 2), the entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is expressed in type 2 alveolar epithelial cells (AT2) that may play key roles in postinjury repair. An imbalance between ACE2 and ACE has also been hypothesized to contribute to lung injury. Objectives: To characterize the expression and distribution of ACE2 and ACE and to compare AT2 with endothelial cell expression in coronavirus disease (COVID-19)-related or -unrelated acute respiratory distress syndrome (ARDS) and controls. Methods: Lung tissue stainings (using multiplex immunofluorescence) and serum concentrations of ACEs were determined retrospectively in two different cohorts of patients. AT2 and endothelial cells were stained in lung tissue for ProSPC (pro-surfactant protein C) and CD31, respectively. Measurements and Main Results: Pulmonary ACE2 expression was increased in patients with COVID-19-related and -unrelated ARDS (0.06% of tissue area and 0.12% vs. 0.006% for control subjects; P = 0.013 and P < 0.0001, respectively). ACE2 was upregulated in endothelial cells (0.32% and 0.53% vs. 0.01%; P = 0.009 and P < 0.0001) but not in AT2 cells (0.13% and 0.08% vs. 0.03%; P = 0.94 and P = 0.44). Pulmonary expression of ACE was decreased in both COVID-19-related and -unrelated ARDS (P = 0.057 and P = 0.032). Similar increases in ACE2 and decreases in ACE were observed in sera of COVID-19 (P = 0.0054 and P < 0.0001) and non-COVID-19 ARDS (P < 0.0001 and P = 0.016). In addition, AT2 cells were decreased in patients with COVID-19-related ARDS compared with COVID-19-unrelated ARDS (1.395% vs. 2.94%, P = 0.0033). Conclusions: ACE2 is upregulated in lung tissue and serum of both COVID-19-related and -unrelated ARDS, whereas a loss of AT2 cells is selectively observed in COVID-19-related ARDS.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Gerard L, Lecocq M, Bouzin C, et al. Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19-related Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2021. PMID: 34449302. doi:10.1164/rccm.202012-4461OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。